Protox announces private placement


    VANCOUVER, April 28 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader
in the development of receptor targeted fusion proteins, today announced that
it intends to raise gross proceeds of up to CDN $1.5 million through a private
placement of common shares of the Company at a price of $0.27 per share. The
Company has retained Canaccord Capital Corporation (Canaccord) to act as lead
placement agent. Canaccord will be provided with an over-allotment option
exercisable up to 48 hours prior to closing to sell additional common shares
of the Company for proceeds of up to another CDN $1.0 million. The maximum
proceeds to be raised under the brokered private placement would be CDN $2.5
    The brokered private placement is subject to all necessary regulatory and
stock exchange approvals. Protox intends to use the net proceeds principally
to finance its clinical activities.
    The securities being issued in the private placement are all subject to a
four-month hold period in accordance with applicable Canadian securities laws.
The securities have not been registered under the U.S. Securities Act of 1933,
as amended, or any state securities laws and, until so registered, may not be
offered or sold in the United States or any state or to, or for the account
of, U.S. persons absent registration or an applicable exemption from
registration requirements. This release does not constitute an offer for sale
of securities in the United States.

    About Protox

    Protox Therapeutics is a leader in advancing novel, receptor targeted
fusion proteins. Two novel drug candidates derived from the company's
INxin(TM) and PORxin(TM) platforms are being developed in three clinical
programs. Protox's lead program, PRX302 (PORxin), is currently being studied
in a Phase 2 placebo controlled trial to treat benign prostatic hyperplasia
(BPH or enlarged prostate). Positive results from a Phase 2 open-label BPH
study were released at the end of 2008 and a phase 2a clinical trial
evaluating PRX302 for the treatment of localized prostate cancer is ongoing. A
Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary
brain cancer has been completed and the drug has received Fast Track
Designation and Orphan Drug Status from the US FDA and EMEA. Protox is also
collaborating with the U.S. National Institutes of Health (NIH) on a research
program focused on the discovery of next generation fully human targeted

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information:

For further information: James Beesley, Senior Director, Investor
Relations, Protox Therapeutics, (604) 484-0975,; Michael Moore, Investor Relations, Equicom
Group, (416) 815-0700 x 241,

Organization Profile

Sophiris Bio, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890